Yamanouchi Shaklee Pharma and J&J/Merck form an agreement for the development of an OTC product using Yamanouchi's Wowtab technology for quick-dissolving tablets that can be taken without water. J&J/Merck Consumer markets Mylanta and Pepcid AC antacids and stomach acid blockers. No OTCs using the Wowtab system are on the market; the J&J/Merck deal is the first such arrangement to be disclosed. Yamanouchi signed an agreement with Glaxo Wellcome recently for an Rx migraine therapy using the technology. Wowtab tablets are hard and stable, allowing bottle or blister packaging, but melt in the mouth in 15 seconds or less without water, the firm says...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.
Lupin became the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster.
The FDA will use electronic health records to “get eyes” on drugs immediately after approval, Commissioner Martin Makary told the DIA 2025 Global Annual Meeting. He also wants to reduce development time with better communication and new approval pathways.
